Argenx Se
ARGX Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 30, 2026
$892.87
KIRA · Stoqly’s AI analyst, in plain words
- Argenx Se had $4.2B of revenue in fiscal 2025, up 88.6% on the year before. Over five years, revenue changed +152.7% a year on average.
- Its operating margin was 24.8%, up 25.8 pts: of every 100 in sales, about 25 is left after running the business.
- Argenx Se made $1.3B of net profit in fiscal 2025.
- Free cash flow was $679M in fiscal 2025, 16.0% of revenue.
Market cap
$59.0B
P/E
45.6x
Revenue
$4.2B
Net income
$1.3B
Free cash flow
$679M
Operating margin
24.8%
Argenx Se in 30 seconds · fiscal 2025
Are sales growing?
+88.6%
Yes. Sales grew 88.6% last year.
Does it make a profit?
30.4%
Yes. It keeps 30.4% of every sale as profit.
Does profit turn into cash?
16.0%
Yes. 16.0% of sales ends up as free cash.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
45.6x
One share costs 45.6 times its yearly profit per share.
What Argenx Se does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 19, 2026
- Legal name
- ARGENX SE
- CIK
- 0001697862
Argenx Se · ARGX · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $497M | $10.0M | $35.5M | $2.3B | $4.2B |
| Revenue growth | 1,105.7% | −98.0% | 254.4% | 6,237.9% | 88.6% |
| Gross margin | — | −193.5% | −231.6% | 89.9% | 89.4% |
| Operating margin | −70.1% | −7,184.7% | −1,196.2% | −1.0% | 24.8% |
| Net income | −$408M | −$710M | −$295M | $833M | $1.3B |
| Net margin | −82.1% | −7,077.5% | −830.4% | 37.0% | 30.4% |
| Diluted EPS | −$7.99 | −$13.05 | −$5.16 | $12.78 | $19.57 |
| Cash | |||||
| Cash from operations | −$607M | −$863M | −$420M | −$82.7M | $685M |
| Capital expenditure | $3.6M | $0.8M | $0.8M | $1.8M | $6.2M |
| Free cash flow | −$610M | −$864M | −$421M | −$84.5M | $679M |
| FCF margin | −122.8% | −8,614.0% | −1,185.2% | −3.8% | 16.0% |
| Share count change | 12.5% | 6.5% | 5.1% | 14.0% | 1.3% |
| Debt and strength | |||||
| Cash and short-term investments | $1.3B | $801M | $2.0B | $1.5B | $3.5B |
| Debt incl. finance leases | — | — | $7.2M | — | — |
| Shareholders' equity | $2.5B | $2.8B | $4.1B | $5.5B | $7.3B |
| Current ratio | 8.4x | 9.2x | 9.7x | 7.3x | 5.2x |
| Interest coverage | −76.2x | −184.4x | −469.1x | −8.8x | 258.2x |
| Returns and quality | |||||
| Return on capital | — | — | −16.3% | — | — |
| Return on equity | −19.4% | −26.5% | −8.5% | 17.4% | 20.2% |
| Return on tangible equity | −17.3% | −26.9% | −7.4% | 15.7% | 18.3% |
| Piotroski F-score | 3 | 1 | 3 | 4 | 4 |
| Altman Z'' | 11.2 | 10.7 | 12.7 | 11.8 | 10.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Argenx Se · ARGX · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $892.87 a share, the company is worth $59.0B: 45.6 times its earnings of the last four quarters.
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001697862). Latest version: stoqly.net/companies/argx. Data updated November 1, 2026. For information only — not investment advice. Check the original filings before relying on any figure.